Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Autoimmune Hepatitis Clinical Trial

Official title:

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04203875
• Other study ID #: Pro00102357
• Status: Terminated
• Phase: Phase 1
• Start date: March 9, 2020
• Est. completion date: July 23, 2020

Study information

• Verified date: November 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether Orencia® (Abatacept) improves outcomes in liver transplant patients with recurrent or de novo AIH (autoimmune hepatitis) that has not responded to previous therapy. AIH that does not respond to steroids or conventional immunotherapy often affects young patients and leads to irreversible liver damage. There is currently no effective therapy for this condition.

Description:

Participants in this study will receive the study drug once a week for 6 months. If the study doctor feels the study drug has been beneficial, participants may receive additional study drug doses for up to an additional 6 months. Participants will continue on follow-up for 1 year after stopping Abatacept. The risks related to participation in this study include potential side effects from the study drug include infusion-related reactions (reactions at the injection site), increase in respiratory adverse events, infections in patients with chronic obstructive pulmonary disease, risk of development of malignancies (cancer) or autoimmune disorders (which may make your current autoimmune disease worse or you can contract new autoimmune diseases). It is unknown if this is drug related. The study doctor will discuss any concerns about this with you prior to receiving treatment. There is the possibility that the participant may experience improvement in their medical condition from participation in this study. However, this benefit cannot be guaranteed. There may be no direct medical benefit to the participant due to their participation. The Investigator hopes that in the future the information learned from this study will benefit other people with this condition.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: July 23, 2020
• Est. primary completion date: July 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for de novo AIH

• Age 18 or older
• Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and a different pre-transplant etiology of liver disease will be eligible.
• Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.
• Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.
• Women of child bearing potential agree to have pregnancy test at screening
• Males agree use of appropriate contraceptives during the active Orenia dosing period Inclusion Criteria for recurrent AIH
• Age 18 or older
• Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and whose original etiology of liver disease was AIH will be eligible.
• Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.
• Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.
• Women of child bearing potential agree to have pregnancy test at screening
• Males agree use of appropriate contraceptives during the active Orenia dosing period

Exclusion Criteria:

• Active systemic infection
• Allergy to abatacept
• Known malignancy in the previous 2 years except for non-melanoma skin cancer
• Pregnancy or breast feeding
• Inability to commit to complete treatment protocol at Duke, as all procedures must be completed at Duke
• Prisoners or those who are compulsory detained
• Inability to read and understand English
• EBV seronegative (if not tested within 2 years prior to study enrollment, then testing will be done prior to study enrollment, results must be positive for study participation)

Related Conditions & MeSH terms

• Autoimmune Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Autoimmune

Intervention

Drug:
• Orencia® (Abatacept)
Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Stuart Knechtle, M.D.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events as reported	Any Adverse Event	within 56 days of last dose
Primary	Number of Infections seen after administration	Any infection	within 56 days of last dose
Primary	Number of malignancies reported	any malignancy	within 56 days of last dose
Secondary	A change in aspartate aminotransferase (AST)	Any change	Baseline and at 6 weeks after start of administration
Secondary	A change in alanine aminotransferase (ALT)	Any change	Baseline and at 6 weeks after start of administration
Secondary	a change in alkaline phosphatase	Any change	Baseline and at 6 weeks after start of administration
Secondary	Change in bilirubin	Any change	Baseline and at 6 weeks after start of administration
Secondary	Change in liver biopsy evidence of AIH compared to pre-treatment	evidence of worsening AIH on biopsy	through study completion, an average of 1 year